Stay updated on Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Only minor formatting and layout tweaks were observed; no core study data or critical page content were changed (e.g., title, NCT number, eligibility criteria, endpoints), and to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T12:49:18.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    - Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.
    Difference
    2%
    Check dated 2025-10-05T17:37:21.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Page now shows Revision: v3.1.0 and removes several pharmaceutical topics (e.g., Drug Safety, Ovarian cancer, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs).
    Difference
    0.3%
    Check dated 2025-09-28T11:13:11.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed as a minor UI change.
    Difference
    0.1%
    Check dated 2025-09-14T00:53:11.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.1%
    Check dated 2025-09-06T21:30:30.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The webpage has been updated to include a comprehensive list of facility names and locations related to ovarian cancer research, along with new publications from PubMed. Notably, the drug olaparib is highlighted in the context of its safety and use in treating malignant epithelial tumors of the ovary.
    Difference
    9%
    Check dated 2025-08-30T15:59:10.000Z thumbnail image

Stay in the know with updates to Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page.